While sarcopenia has been associated with poor prognosis in multiple types of cancer, its predictive role in the context of first-line treatment combining PD-(L)1 inhibitors with platinum-based chemotherapy (CITx) remains unclear in advanced NSCLC.<h4>Methods</h4>In a single-centre retrospective cohort, patients with advanced NSCLC without actionable genomic alterations who received either CITx (n = 552) or platinum-doublet chemotherapy alone (CTx; n = 622) were analysed. This evidence concerns the gene CD274 and sarcopenia.